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Background: Extracellular transglutaminase-2 binds heparan sulfate and has adhesive/signaling pro-fibrotic functions.
Results:Two clusters of basic residues, distal in the linear sequence of transglutaminase-2, are required for heparin binding and
cell adhesion.
Conclusion: Folding of the transglutaminase-2 protein brings basic residues in close proximity to form a functional heparin
binding domain.
Significance:Mapping the heparan sulfate binding domain will enhance design of transglutaminase-2 inhibitors.
Heparan sulfate proteoglycans are critical binding partners
for extracellular tranglutaminase-2 (TG2), a multifunctional
protein involved in tissue remodeling events related to organ
fibrosis and cancer progression. We previously showed that
TG2 has a strong affinity for heparan sulfate (HS)/heparin and
reported that the heparan sulfate proteoglycan syndecan-4 acts
as a receptor for TG2 via itsHS chains in twoways: by increasing
TG2-cell surface trafficking/externalization and by mediating
RGD-independent cell adhesion to fibronectin-TG2 matrix
during wound healing. Here we have investigated themolecular
basis of this interaction. Site-directedmutagenesis revealed that
either mutation of basic RRWK (262–265) or KQKRK (598–
602) clusters, forming accessible heparin binding sequences on
the TG2 three-dimensional structure, led to an almost complete
reduction of heparin binding, indicating that both clusters con-
tribute to form a single binding surface. Mutation of residues
Arg19 and Arg28 also led to a significant reduction in heparin
binding, suggesting their involvement. Our findings indicate
that the heparin binding sites onTG2mainly comprise two clus-
ters of basic amino acids, which are distant in the linear
sequence but brought into spatial proximity in the folded
“closed” protein, forming a high affinity heparin binding site.
Molecular modeling showed that the identified site can make
contact with a single heparin-derived pentasaccharide. The
TG2-heparin binding mutants supported only weak RGD-inde-
pendent cell adhesion compared with wild type TG2 ormutants
with retained heparin binding, and both heparin binding clus-
ters were critical for TG2-mediated cell adhesion. These find-
ings significantly advance our knowledge of how HS/heparin
influences the adhesive function of TG2.
Transglutaminase type 2 (TG2)3 (EC 2.3.2.13) belongs to an
emerging category of proteins with distinctmolecular activities
that function both inside and outside the cell and transit the
plasma membrane by unconventional secretion (1, 2). Outside
the cell TG2 regulates the extracellular matrix (ECM) organi-
zation andmodulates cell-ECMadhesion andoutside-in signal-
ing (3), whereas in the intracellular environment TG2 partici-
pates into signaling events leading to regulation of cell survival,
particularly in response to cell wounding, hypoxia, and oxida-
tive stress (4–6). TG2 is ubiquitously expressed and plays a
pleiotropic role in a variety of pathophysiological conditions
related to tissue remodeling including cancer development,
organ fibrosis, and neurodegeneration (7–11). Protein transami-
dation, leading to (-glutamyl)lysine intra- or intermolecular
isopeptide bonds (“protein cross-links”), is the enzymatic reac-
tion for which TG2 is better recognized, which is regulated by
Ca2 binding and guanine nucleotide dissociation, a condition
favored in the extracellular environment or after cell injury and
loss of Ca2 homeostasis (12). Furthermore, TG2-mediated
protein deamidation ofGln residues contributes to the adaptive
immunoresponse induced in gluten sensitivity diseases (13). In
the intracellular environment TG2 can serve as a an unconven-
tional GTPase whose GTP binding and hydrolysis site is inte-
grated with the Ca2-regulated transamidase active site (14,
15). In the ECM the role of TG2 is largely linked to its interac-
tion with fibronectin, which occurs via the N-terminal -sand-
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wich domain of TG2, leading to cell-matrix adhesion, cell
migration, and signaling (3, 12, 16, 17). The extracellular func-
tion of TG2 only partly depends on protein cross-linking (e.g.
leading to fibronectin remodeling). TG2 supports adhesion-
mediated cell signaling through a well described non-enzy-
matic function by acting as a cell surface integrin-1 co-recep-
tor for fibronectin (18) or by ligating syndecan-4 (sdc-4)
receptor once deposited in the ECM in a TG2-fibronectin het-
erocomplex (19, 20).
TG2 contributes to the regulation of extracellular and intra-
cellular events. However, how TG2 dual location may be coor-
dinated to allow for flexibility of localization/function and how
the balance between catalytically active and inactive TG2 is
maintained in the extracellular environment remains to be clar-
ified (21). It has been recently proposed that TG2 is external-
ized via recycling endosomes in which it is delivered by binding
to phospholipids and an unknown endosomal receptor(s),
based on amodel of fibroblasts expressing exogenous TG2 (22).
In our laboratory we previously identified a strong affinity of
TG2 for heparan sulfate (HS) glycosoaminoglycans and its
association with the aforementioned HS proteoglycan receptor
sdc-4.We demonstrated that theHS chains of sdc-4 have a dual
role in regulating TG2 function; that is, by controlling the cell
surface trafficking/ECMdistribution of TG2 in vitro and in vivo
during experimental kidney fibrosis (23, 24) and by mediating
RGD-independent cell adhesion induced bymatrix TG2 in het-
erocomplex with fibronectin (19, 20, 25). This alternative cell
adhesion pathway complements the classic integrin-dependent
RGD pathway, leading to RGD-independent activation of pro-
tein kinase C, focal adhesion kinase, and ERK1/2 protein
kinases (20). This process is particularly relevant in situations of
cell damage/matrix fragmentation and increased deposition of
TG2 in thematrix once integrin-mediated signaling is compro-
mised (3).
Heparan sulfate (26) glycosoaminoglycans are well recog-
nized regulators of cell functions by acting as signaling co-re-
ceptors, modulators of tissue distribution, and cellular traffick-
ing for a variety of molecules. HS is a complex polysaccharide
consisting of disaccharide units and is linked to specific cell
surface proteins (e.g. the aforementioned syndecans and gly-
picans) and ECM proteins (agrin, perlecan, collagen XVIII).
TheHS chains consist of alternatingN-acetylated orN-sulfated
glucosamine units (GlcNAc orN-sulfoglucosamine) and uronic
acids (glucuronic acid or iduronic acid). The assembly of HS
chains on core proteins is characterized by great variability and
processing reactions (GlcNac N-deacetylation, N-sulfation,
epimerization, and O-sulfation), which progress at different
extents to generate patterns of highly negatively charged bind-
ing sites responsible for binding to a variety of protein ligands
(among which fibroblast growth factor (FGF)/FGF receptor is
well documented (27)).
Although the crystallographic structure of TG2 has been
defined (28, 29), the heparin binding site in TG2 has not been
determined.Given the potential key role ofHS proteoglycans in
controlling the trafficking and the extracellular adhesive func-
tions of TG2 in vitro and in vivo, we have begun investigating
the nature of this interaction. In this study we have mapped a
high affinity heparin binding site on TG2 and showed that it
comprises two distant clusters of basic amino acids that are
brought into close proximity on the folded protein. We have
also shown that the identified heparin binding site is critical for
cell adhesion to TG2-fibronectin matrix. These data signifi-
cantly advance our knowledge of how HS/heparin interacts
with and influences the adhesive function of TG2.
EXPERIMENTAL PROCEDURES
Protein Expression, Purification, and Analysis—Human TG2
cDNA (30) was subcloned into pET21a() (Novagen) between
NheI and HindIII restriction enzyme sites (pET21a()TG2).
Using pET21a()TG2 as reaction template, mutants of resi-
dues predicted to be involved in heparin bindingwere produced
by QuikChange II site-directed mutagenesis (Stratagene) using
PfuUltra high fidelity DNA polymerase and mutagenic oligo-
nucleotide primers (Sigma Genosys) (supplemental Table 1).
Single ormultiple amino acids residues were substituted to ser-
ine as summarized in Table 1. The point mutations were con-
firmed by sequencing using standard T7-Promoter Primer or
T7-Terminator Primer (SourceBioscience). To produce TG2
protein, pET21a()TG2 was expressed in BL21 (DE3) cells
(Novagen). After cell growth in Luria Bertani medium contain-
ing ampicillin (100 g/ml) (up to A600 0.6), expression of
recombinant His-tagged TG2 was induced by the addition of
isopropyl 1-thio--D-galactopyranoside (1 M) and incubation
at 20 h at 20 °C as described (31). Mutant (M) TG2 constructs
were expressed and purified using the same protocol except for
M1a, M1b, and M1c whose expression was induced by 100 M
isopropyl 1-thio--D-galactopyranoside. After induction, cells
were recovered by centrifugation (4000 g at 4 °C for 30 min).
The pellet was resuspended in lysis buffer (50 mM Na3PO4 (pH
8.0), 300 mM NaCl) supplemented with 10 mM imidazole and 1
mM EDTA, lysed by sonication (Soniprep) for 60 s (amplitude
12), and incubated with 2 mg/ml lysozyme on ice for 30 min
(Sigma) followed by 3more rounds of sonication. After centrif-
ugation (40,000  g at 4 °C for 45 min), the supernatant was
applied to a column holding 15 ml of Ni-His60 Superflow resin
(Clontech). The columnwas washed once with lysis buffer con-
taining, first, 10 mM imidazole and then 40 mM imidazole until
no proteins were detected in the wash buffer (as monitored by
the UV flow cell of Biologic HR chromatography (Bio-Rad)).
TG2 was eluted in buffer containing 400 mM imidazole. Frac-
tions containing TG2 (as monitored by SDS-PAGE) were
pooled and exchanged in 50 mM Tris-HCl (pH 8.0), 50 mM
NaCl, 2 mM DTT and 1 mM EDTA. They were then further
purified on aHi-TrapHP column (GEHealthcare) employing a
gradient ofNaCl (0–1M) in 50mMTris-Cl (pH 8.0), 2mMDTT,
and 1 mM EDTA. Recombinant TG2 was eluted between at
330–440 mM NaCl, concentrated using VivaSpin 30,000 Mr
cutoff concentrator (Vivabioscience) and exchanged in 50 mM
Na3PO4 (pH 8.0), 150mMNaCl, 2mMDTT, 1mM EDTA. After
the addition of maltodextrin to the concentration of 5% (w/v),
the protein was stored at 80 °C. Proteins were analyzed by
10% (w/v) acrylamide gels for SDS-PAGE followed by Instant
Blue staining (Expedeon) and Western blotting as previously
described (23) using horseradish peroxidase-conjugatedmouse
anti-His6 antibody (Roche Applied Science).
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Thermal Shift Assay—Thermal shift assay analyses were per-
formed using a IQ5 real-time PCR system as previously
described (32). Briefly, wild type (wt) or mutant TG2 (23 l at
0.5 mg/ml) were mixed with 2 l of a 100 SYPRO Orange
solution in water (Molecular Probes, Invitrogen). Samples were
heated from 20 to 100 °C at 1 °C/min rate. Protein unfolding
was followed by fluorescence measurement (excitation/emis-
sion 583/610 nm) every 0.2 s. Melting temperature (Tm) was
determined for each sample by analyzing the collected data
with a custom differential scanning fluorimetry analysis soft-
ware as described before (33).
TG2 Activity Assay—TG2 activity was measured by the
incorporation of biotinylated cadaverin into fibronectin as
described previously (34). Briefly, recombinant and mutant
TG2 (100 ng) were incubated in fibronectin-coated 96-well
plates in reaction buffer (50mMTris-HCl (pH 7.4), 5mMCaCl2,
10 mM DTT, and 0.1 mM biotinylated cadaverine) in a final
volume of 100 l for 2 h at 37 °C. Background TG2 activity
valueswere obtained by replacing 5mMCaCl2with 5mMEDTA
in the reaction buffer. The reactionwas stopped by the addition
of PBS (pH 7.4) containing 10 mM EDTA. The level of incorpo-
rated biotin-cadaverine into fibronectin was revealed by incu-
bation with extravidin peroxidase followed by the addition of
3,3,5,5-tetramethylbenzidine at fixed times and stopped by
0.5 M H2SO4. Spectrophotometric absorbances were measured
at 450 nm. Background TG2 activity values in the presence of
EDTA were subtracted from activity values at 5 mM Ca2. Cal-
ibration curves were obtained with known units of commercial
recombinant TG2 (Sigma). Ca2activation of wt and mutant
TG2 was determined at increasing concentrations of added
Ca2 (0–5 mM). Guanosine-5-triphosphate (GTP) inhibition
was assayed at increasing GTP concentrations (0–2 mM) in the
presence of a fixed concentration of Ca2 (150 M).
Stabilization of TG2 into “Open” Conformation—TG2 was
incubated with active-site directed inhibitors R283 (1,3-di-
methyl-2-[(2-oxopropyl)thio]imidazolium chloride) (30M) or
Boc-Don (Boc-DON-Gln-Ile-Val-OMe) (3 M), both from
Zedira GmbH, in the presence of 10 mM CaCl2 for 5 min at
37 °C according to the manufacturer’s instructions. Commer-
cial open His-TG2 (Open tTGTM, Zedira GmbH), produced in
insect cells and stabilized in the open conformation via the pep-
tidomimetic blocker ZED754 by the manufacturer, was also
utilized.
Biotinylation Procedure and Heparin Immobilization—Hep-
arin (6 kDa) (Sigma) was biotinylated at the reducing end (Bio-
tin-LC-hydrazide, Pierce) as described previously (38) and
immobilized on a CM4 Biacore sensorchip (GE Healthcare)
using an amine coupling kit. Briefly, a Biacore 3000 system (GE
Healthcare) was equilibrated with running buffer HBS-EP (10
mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P20,
pH 7.4) at 5 l/min, and the temperature was maintained at
25 °C. Two flow cells of a CM4 sensorchip were activated with
50 l of a mixture of 0.2 M l-ethyl-3-(3-dimethylaminopropyl)
carbodiimide, 0.05 MN-hydroxysuccinimide before injection of
50 l of streptavidin (0.1 mg/ml in 10 mM acetate buffer (pH
4.2)). Remaining activated groups were blocked with 50 l of
ethanolamine 1 M, pH 8.5. Typically, this procedure allowed
coupling of approximately  2500 resonance units of strepta-
vidin. Biotinylated heparin (5 g/ml in HBS-EP containing 0.3
M NaCl) was then injected on one of the two streptavidin sur-
face (the other one being a negative control) until an immobi-
lization level of 50 resonance units was achieved. Both flow cells
were then conditioned with several injections of 1 min of 0.1%
SDS and 4 min of 2 M NaCl.
TG2/Heparin Interaction—For binding assays, test samples
(wt or mutant TG2) were diluted in HBS-EP buffer maintained
at 25 °C and injected over both a reference and the heparin
surfaces at a flow rate of 20 l/min for 5 min after which the
formed complex was washed with another 5 min of running
buffer. The sensorchip surfaces were regenerated with a 1-min
pulse of 0.1% SDS and a 4-min pulse of 2 M NaCl. In a typical
analysis, six different TG2 concentrations were injected.
Apparent dissociation constants (KD) were estimated by fitting
the steady state values at equilibrium (Req) assuming one bind-
ing site with Req  Rmaxeq/(KD  c) and by plotting (Req)
divided by the concentrations of injected TG2 (c) against the
Req for different concentrations of the protein (Scatchard
analysis).
Molecular Modeling—Among the three available crystal
structures of human TG2 (28, 29), the structure of the complex
with ATP solved at 3.1 Å (PDB code 3LY6) (29) was selected for
the modeling study. It corresponds to a closed conformation,
and very few residues are missing in the structures. The resi-
dues identified by mutagenesis studies as interacting with hep-
arin were graphically analyzed, with special attention for resi-
dues Arg28, Arg 262, Arg 263, Lys265, Arg 598, Lys 600, Lys 602, and
Lys634. When necessary, the orientations of the side chains of
these amino acids were modified to point toward the solvent
and interact favorably with negatively charged ligands. The ori-
entation of the side chain of Glu632 was also modified to break
the salt chain with Lys634, which then could act as possible
ligand binding residue. All calculations were performed using
the Schro¨dinger suite. TheOPLS-2005 force-field (35)was used
for the protein preparation, and the residues charges were
assigned considering a pH of 7.0. The receptor model was sub-
jected to a short energyminimization procedure of 100 steps of
conjugate gradient using the Impact facility of the Schro¨dinger
Suite with a dielectric constant of 1, a residue-based non-
bonded cut-off of 12 Å, and a 10-step interval for update of the
non-bonded list.
For the docking calculations, a pentasaccharide of heparin
with Ido2s at reducing and non-reducing ends was extracted
from the PDB structure 1HPN (36) with iduronic ring in 1C4
conformation. A preliminary conformational search was per-
formed on the pentasaccharide using the module Macromodel
of the Schro¨dinger Suite 2010 (MacroModel 9.1, Schro¨dinger,
Inc., L.L.C., New York, NY) while constraining the conforma-
tion of all rings. A set of 16 low energy conformers was obtained
and submitted to a docking calculation using Glide version 5.6
(Schro¨dinger Suite 2010) (37). The box used for the docking
studies was generated from a manual docking of a hexasaccha-
ride in the vicinity of the residues characterized frommutagen-
esis studies. A flexible docking in standard precision was per-
formed allowing sampling of the nitrogen inversions but not of
the ring conformations. For each of the 16 conformers, 5000
initial poses were selected, and the best 400 poses were sub-
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jected to post-docking minimization using 100 steps of conju-
gate gradient. The ligand poses were ranked according to their
Glide scores.
Assay of RGD-independent Cell Adhesion to TG2-Fibronectin
Matrix—The adhesion of Swiss 3T3 albino fibroblasts to TG2-
fibronectin was assayed as described before (19). Briefly,
fibronectinmatrix (5g/ml) was immobilized on tissue culture
plastic (wells of 96-well plates), blocked in 3% (w/v) lipid-free
milk protein (Marvel), and supplemented with TG2 protein (20
g/ml) in the presence of 2 mM EDTA. Tomeasure RGD-inde-
pendent cell adhesion, exponentially growing cells were prein-
cubated with GRGDTP synthetic peptide (100 g/ml) or simi-
lar concentrations of control inactive GRADSP peptide
(Merck) in suspension in serum-free Dulbecco’s modified
Eagle’s medium (DMEM) before being seeded on fibronectin
matrix alone or in complexwith TG2. After 20min of cell adhe-
sion, the adhered cells were stained with May Gru¨nwald and
Giemsa stain (Sigma) and assessed in terms of cell attachment
and cell spreading as described previously (23) using ImageJ (9
images/well). The presence of wt andmutant TG2 immobilized
on fibronectin was confirmed by an ELISA-type assay using
HRP-conjugated anti-His6 antibody (Roche Applied Science)
as previously described (19).
Statistics—Statistical significance was tested by one-way
analysis of variance using Dunnett’s post-test (EC50 for Ca2
and IC50 for GTP) or Bonferroni’s post-test (cell adhesion
assay); *, p 0.05; **, p 0.01; ***, p 0.001.
RESULTS
Identification of Potential Heparin Binding Sites—Identifica-
tion of heparin binding sites on proteins remains a complex
issue. Early work, based on heparin binding protein sequence
comparison, led to the proposition of two binding consensus
sequences, XBBXBX and XBBBXXBX, where B stands for a
basic, and X is for a neutral/hydrophobic amino acid (38). This,
however, does not exclude that patterns of positively charged
residues comprise distant amino acids clustered by the protein
folding (39). Examination of the TG2 sequence (Fig. 1A) reveals
the presence of several basic residues (38 Arg and 32 Lys resi-
dues), some of which are organized into two typical heparin
binding site, i.e. RRWK and KQKRK (positions 262–265 and
598–602, respectively). Analysis of the three-dimensional
structure of the protein (Fig. 1B) showed that these two clusters,
although distant on the protein sequence, are close to each
other on the TG2 surface. Further examination of the protein
structure also revealed that three basic residues, Arg19 and
Arg28 and Lys634 are in close proximity of these two clusters.
Thus, based on this analysis, TG2 mutants targeting these
domains were produced as well as two further residues, Lys202
and Lys205, which form a well exposed positively charged clus-
ter on the opposite face of the protein, and Arg580 in the GTP
binding pocket.
Production and Purification of Recombinant wt and Mutant
TG2—Full-length human TG2 was expressed and purified by
using a modified version of the two-step purification process
developed by Piper et al. (31). Thirteen sequence positions of
TG2 (30) were selected for mutagenesis (Arg19; Arg28; Lys202/
Lys205; Arg 262; Arg 263; Lys265; Arg580; Lys598/Lys600/Arg 601/
Lys602; Lys634), and a total of nine single and multiple site
mutant constructs were generated where the basic residues
(Arg, Lys) were replaced by Ser (which better maintains a cer-
tain level of hydrophilicity than the Ala residue). All the TG2
mutants were expressed at milligram levels with purity similar
FIGURE 1. Identification of potential heparin binding sites on the TG2 sequence. A, shown is the amino acid sequence of TG2. The basic residues Arg and
Lys are in bold, and the colored boxes indicate residues investigated bymutagenesis. B, the structure of TG2 (PDB code 3LY6) shows the surface localization of
residues corresponding to TG2 mutants M1 and M3 (yellow), M2 and M6 (red), M4 and M5 (green), and M7 (blue). The drawings were prepared with PyMOL.
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to wt TG2 (supplemental Fig. 1). To test whether the TG2
mutants retained the typical transamidating activity of TG2,
which is dependent on Ca2 and regulated by guanine nucleo-
tides, wemeasured theCa2 requirement for themutants com-
pared with wt TG2. Dose-response curves for Ca2 activation
were obtained by increasing the concentration of added Ca2
(0–5 mM) (Fig. 2A). All the TG2 mutants showed Ca2 depen-
dence. Wt TG2 reached half-maximal activation at 90 M
Ca2 concentration (Table 1). There were no significant differ-
ences in EC50 for Ca2 activation between wt TG2 and the
mutants except for M1a (Arg262), M1b (Arg263), and M7
(Lys634), which reached30–40% activity at the EC50 (Ca2) of
wt TG2. However, only M1b displayed a significantly lower
level of specific activity than the wt enzyme at saturating levels
of Ca2 (Table 1). The GTP inhibition of wt and mutant TG2
was evaluated in the presence of 150 M Ca2 (which corre-
sponds to 70% of maximum activity of wt TG2). GTP was
capable of inhibiting all the mutant enzymes similarly to wt
TG2 (Fig. 2B), with only M1a (Arg262) and M4 (Arg-19) being
slightly more and less sensitive, respectively, to GTP inhibition
(Table 1). Mutant M6, corresponding to the GTP binding resi-
due Arg580, was found not to be GTP-dependent, as previously
shown (40). All together these results indicate that all the TG2
mutants, except for the GTP binding mutant M6, retained the
ability to be modulated by Ca2 and GTP as wt TG2. It can be
concluded that all these mutations do not disrupt the bifunc-
tional property of TG2, indicating that the proteins were prop-
erly folded. Thermal shift analysis showed that the TG2
mutants had very similar stability to wt TG2, a finding that is
consistent with their correct folding (supplemental Fig. 2).
Therefore, the TG2 mutants were next investigated for their
heparin binding properties.
Experimental Identification of TG2 Amino Acids Involved in
Heparin Binding—The binding properties of the wt and
mutated recombinantTG2were tested using a solid phase assay
in which biotinylated heparin was immobilized on top of a
streptavidin-coated sensorchip. This systemmimicked to some
extent the cell membrane-anchored proteoglycan, and surface
plasmon resonance spectroscopy was used to measure changes
in the refractive index caused by the interaction that occurred
when TG2 was flowed across the immobilized heparin surface.
Dose-response experiments were performed with the wt TG2
injected in the 66–500 nM range. The association phase (from
100 to 400 s) was allowed to proceed to equilibrium (Fig. 3A),
and affinity data were derived as described under “Experimen-
tal Procedures.” This returned an affinity of KD  181 nM. As
heparin is heterogeneous in sequence and is thus likely to dis-
play different binding sites, the above calculated value should
be regarded as an “average affinity” constant. Nevertheless, this
indicated a relatively strong affinity between TG2 and heparin.
Next, the same assay was used to determine the binding
strength of the different TG2 mutants. Each of the residues of
the first BBXB cluster (Arg262, Arg263, and Lys265) was found
critically important for heparin recognition, as none of the cor-
responding mutants (M1a, M1b, and M1c) strongly bound to
the immobilized glycosoaminoglycan (Fig. 3, B–D). Similarly,
the mutant corresponding to the second cluster (M3; KQKRK)
was strongly impaired in its ability to bind heparin (Fig. 3E).
Then, to investigate whether residues Arg19 and Arg28, both
located close to the above-analyzed residues, could be part of
the binding site, the TG2mutants (M4 andM5) corresponding
to these two residues were injected over the heparin surface.
Although thesemutants still interacted with heparin, they both
displayed defects in heparin binding (Fig. 3, F andG). The TG2
mutantM7, corresponding to residue Lys634, bound verywell to
heparin but at a much lower rate, as equilibrium was not
reached after the 5-min association phase, compared with wt
TG2 (Fig. 3H), supporting its involvement in heparin recogni-
tion. Finally, we also analyzed the effect of two additional
mutants, the M2 mutant (Lys202, Lys205) whose mutated resi-
dues are located on the opposite face of the protein, and theM6
mutant (Arg580). Both displayed strong binding (Fig. 3, I and J),
returning affinity values of 162 nM for M2 and 189 nM for M6,
thus, virtually identical to that of the wt protein. Altogether,
these data showed that the TG2 heparin binding site is a com-
posite one, as both clusters 262–265 (M1) on one side and 598–
602 (M3) on the other side are strictly required for the interac-
tion to take place, with a participation of residues 19 (M4), 28
(M5), and 634 (M7).
Binding of Conformationally Open and Closed TG2 to
Heparin—In the folded conformation the two positive clusters
262–265 (M1) and 598–602 (M3) are spatially close (Fig. 1),
whereas in the open “active” conformation these sites are spa-
tially distant (41). To investigate the affinity of TG2 for heparin
TABLE 1
Calcium activation and GTP inhibition of transglutaminase activity
The activity of transglutaminase was determined at increasing concentrations of Ca2 or GTP as described under “Experimental Procedures.” Activities are reported as the
percentage of maximal activity. EC50 for Ca2 activation (Fig. 2A) and IC50 for GTP inhibition (Fig. 2B) were estimated using GraphPad Prism. TG specific activity values
at the plateau Ca2 level (5 mM) are also shown. All values are expressed as the means S.E. for at least 3 independent experiments. Significant differences between wt and
mutant TG2 are shown.
Protein Substitution EC50 (Ca2) IC50 (GTP) TG specific activity
M M Units/mg
TG2 wt 86 9 142 24 3.9 0.4
M1a R262S 258 32a 23 5b 2.8 0.3
M1b R263S 195 56b 79 15 2.7 0.1b
M1c K265S 123 13 182 17 3.1 0.1
M2 K202S/K205S 68 4 145 23 3.8 0.3
M3 K598S/K600S/R601S/K602S 136 13 148 26 3.6 0.2
M4 R19S 67 7 254 8b 3.7 0.5
M5 R28S 115 17 64 27 3.4 0.2
M6 R580S 64 3 No inhibition 4.8 0.4
M7 K634S 260 30a 199 36 3.2 0.2
a p 0.001.
b p 0.05.
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in the open and closed conformation, we stabilized TG2 in the
open form by alkylation of the active site using two different
TG2 inhibitors, R283 and Boc-DON, as described under
“Experimental Procedures.” TG2 in complex with either the
covalently bound inhibitors displayed strongly reduced binding
to heparin compared with untreated TG2 (Fig. 4A). This find-
ing was further investigated by comparing the heparin binding
properties of the Open-tTGTM, a commercially available His-
tagged TG2 whose open conformation is experimentally con-
firmed, with that of His-tagged wt TG2 produced by the same
manufacturer (Fig. 4B). Our data show that TG2 does not bind
heparin in the linear open structure.
Docking Calculations—The low energy conformers of the
pentasaccharide mimicking heparin were docked in the TG2
model as described under “Experimental Procedures.” The
resulting poseswere ranked according to their Glide scores that
ranged between 5.2 and 2. Five representative solutions
from the docking calculations are displayed in Fig. 5A. All five
pentasaccharides lie in a crevasse at the protein surface that is
surrounded by basic amino acids. Each pentasaccharide does
not interact with all of the basic amino acids that are labeled in
Fig. 5A, but with a subset of them, depending upon their local-
ization and orientation. Among the five pentasaccharides, the
(,) angles of the iduronic acid-GlcNbond and of the iduronic
acid-GlcN bond are centered around values of (71°  11,
111°  60) and (67°  22, 63°  37), respectively. The average
values are similar to the ones observed in many heparin-bound
crystal complexes (42), and the deviations are mostly on the 
angle, in agreement with the previously calculated energymaps
of the heparin disaccharides (43). The bound conformations
present, therefore, some flexibility ranging from a fully
extended shape to a curved shape.
The solution displayed in Fig. 5B has been selected among
the Glide high scores on the basis of its strong interaction with
basic amino acids and its extended shape. The position of
reducing and non-reducing end could be easily extended to a
polysaccharide. The selected solution demonstrates that a pen-
tasaccharide can easily establish strong salt bridges between
sulfate or acidic groups and the basic amino acidsArg28, Arg262,
Arg263, Lys265, Lys 600, and Lys634. Additional hydrogen bonds
are rare. In this pose they appear only between N-sulfate and
Asn266 and between O-2 of iduronic acid and Gln633 (not
shown). Arg262 has a central location in the basic patch consti-
tuted byArg262, Arg263, Lys265 and establishes contacts not only
with the sulfate group of central iduronic residue but also with
the ring oxygen.
Analyses of the 16 best docking poses (Fig. 5, A and C)
demonstrated the plasticity of the interaction. The basic amino
acids described above are generally involved in contact with a
sulfate but not to a specific one in the pentasaccharide
sequence.
Importance of TG2-Heparin Binding Site in Support of TG2-
mediated RGD-independent Cell Adhesion—We have previ-
ously shown that extracellular matrix TG2 supports RGD-in-
dependent cell adhesion and that this represents a rescue cell
pathway in situations of matrix fragmentation during tissue
repair, when TG2 is abundantly deposited in a protease-resis-
tant complex with fibronectin (19, 20). Cell binding to TG2-
fibronectin requires a direct interaction of TG2 with the HS
chains of sdc-4 (23). It is, therefore, anticipated that ligation of
cell surface sdc-4 by the heparin binding site of TG2 would be
required. Having identified the heparin-binding site within
TG2, we investigated the effects of its mutation in TG2-medi-
ated RGD-independent cell adhesion. For these studies we used
Swiss 3T3 fibroblasts as a cell model (19). Among the heparin
bindingmutant TG2proteins, we testedM1c, corresponding to
the first BBXB cluster (Lys265), and M3, corresponding to the
second heparin binding cluster BXBBB (Lys598/Lys600/Arg601/
Lys602). As showed earlier in this study, these mutants had no
residual heparin binding affinity (Fig. 3) andwere biochemically
very similar to the wt enzyme (Fig. 2). We also included TG2
mutants with retained heparin binding properties, M2, corre-
sponding to Lys202/Lys205, andM6, corresponding toArg580. wt
and mutant TG2 proteins were allowed to associate with
fibronectin as previously described (19, 20). Measurements of
TG2 bound to fibronectin by an ELISA-type assay showed sim-
ilar fibronectin associations between wt and mutant TG2 pro-
teins (supplemental Fig. 3A). Next, cells were allowed to adhere
on fibronectin alone or fibronectin supplemented with either
wt ormutant TG2 proteins, in the presence of competitive con-
centrations of soluble RGD peptide or control inactive RAD
peptide (19, 20). As shown in Fig. 6, by blocking fibronectin
binding to 51 integrins, the RGD peptide significantly
reduced cell attachment and spreading on fibronectin (FN) to
50% that of the control value (FN with or without RAD pep-
tide). In contrast, the RGD peptide did not significantly com-
pete with 51 integrin-cell attachment and spreading when
cells were seeded on fibronectin in complex with wt TG2 (FN-
TG2), whichwas conducive of RGD-independent cell adhesion,
as previously shown (19). However, when cells were allowed to
adhere on fibronectin in complexwith the heparin bindingTG2
mutants (FN-M1c andFN-M3) in the presence of RGDpeptide,
cells only reached half the control cell attachment and
spreading values (FN with or without RAD peptide). The TG2
mutants with retained heparin binding (FN-M2 and FN-M6)
still supported RGD-independent cell adhesion. In conclusion,
the heparin binding TG2 mutants M1c and M3 failed to com-
pensate the loss of RGD dependence in terms of number of
attached cells and cytosolic morphology. The result shows that
the heparin binding site of TG2 that we have identified is
responsible for stimulating RGD-independent cell adhesion.
FIGURE2.CalciumactivationandGTP inhibitionofwtandmutantTG2activity.A, the transamidatingactivity of TG2 (13nM)was assayedat increasingCa2
concentrations (10, 25, 50, 100, 250, 500, 1000, 2500, 5000M) as described under “Experimental Procedures.” B, TG transamidation was assayed at increasing
concentrations of GTP (10, 50, 100, 200, 500, 1000, 2000M) in the presence of 150MCa 2. Data are expressed as a percentage of themaximal TG activity for
each protein and are presented as the mean S.E. of five (A) and three (B) independent experiments carried out in triplicate. Sigmoid curves were fitted to
“sigmoid dose-response (variable slope)” using GraphPad Prism. R2 was 0.93.
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FIGURE3.BindingofwtandmutantTG2to immobilizedheparin.WtTG2(A),mutantsM1a (B),M1b(C),M1c (D),M3 (E),M4 (F),M5 (G),M7 (H),M2 (I), andM6(J)were
injected over a heparin-activated surface at a flow rate or 20 l/min for 5 min, after which running buffer was injected, and the response in resonance units was
recorded as a function of time. Each set of sensorgramswas obtainedwith TG2molecules at (from top to bottom) 500, 333, 222, 150, 100, and 66 nM. K, steady state
valuesatequilibriumplottedagainst the injectedconcentrationofWT-TG2and fitted toReqRmaxeq/(KD c) are shown. Inset, Scatchardplot (Req/cversusReq)of the
correspondingdata.Req values are the steady state values at equilibrium recordedat the endof the associationphase, and c is the concentrationof injectedproteins.
Samples for which the association phase reached equilibrium (wt, M2, andM6)were analyzed similarly. Experimentswere performed in duplicate.
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Although the structure of fibronectin-bound TG2 is not
known, by measuring its transamidating activity in cell culture
medium we have confirmed that, when immobilized on
fibronectin, His-tagged TG2 loses most of its transamidating
activity despite activating concentrations of Ca2 in DMEM
(1.8 mM). The activity is only partly regained by the addition of
DTT (supplemental Fig. 3B) (19). In this form fibronectin-as-
sociated TG2 retains heparin recognition compared with
fibronectin-associated Open-tTGTM when assayed at equilib-
rium by plate binding assay (supplemental Fig. 3C) (23). We
conclude that within the fibronectin-TG2 heterocomplex, TG2
bears an inactive conformation with retained heparin binding.
DISCUSSION
There is evidence that HS proteoglycans mediate the biolog-
ical activity of TG2 in at least twoways; first, by controllingTG2
cell surface trafficking and externalization (23), and second, by
acting as cell surface adhesion receptors for TG2 once it is
released and deposited in a heterocomplex with FN (19, 20, 25).
As an increased externalization of TG2 has been implicated in
several different pathologies, investigating the nature of the
TG2-HS association is important to assist in determining its
physiological role in vivo and to allow the rational control of this
interaction. We have previously reported that TG2 interacts
with HS or its highly sulfated analog heparin strongly, with low
nanomolarKD values (23).Herewehave investigated the nature
of the binding site and characterized, for the first time, the
residues involved in this interaction.
Analysis of the three-dimensional structure of TG2 protein
revealed clusters of positively charged amino acids on the TG2
surface forming typical heparin binding sequences (38) and
spatially close individual basic amino acids that are potentially
accessible by HS chains. Testing these positions of possible HS
binding by site-directed mutagenesis revealed that mutation of
basic cluster KQKRK (598–602) was associated with an almost
complete reduction of heparin binding (Biacore analysis) com-
pared with the wt enzyme. It also showed that mutation of the
FIGURE 4. Binding of open TG2 to immobilized heparin. A, wt TG2 either
stabilized in the open conformation by the inhibitors R283 (red trace) and
Boc-DON (green trace) in thepresenceof 10mMCa2or assayed inbufferwith
2mMEDTA (blue trace) is shown. B, Open-tTGTM (red trace) and commercial wt
TG2 in buffer with 2 mM EDTA (blue trace) is shown. Proteins were injected at
200 nM over a heparin-activated surface and analyzed as described in Fig. 3.
FIGURE 5. A, shown is superposition of the accessible surface of TG2 with five
docked pentasaccharides selected among the 16 with higher GLIDE scores
and representing the range of available conformations. B, selection of one
poseamong the16best oneswith representationof hydrogenbonds tobasic
amino acids is shown.C, shown is the total number of hydrogenbonds for the
16 best poses as a function of the involved carbohydrate sulfate group and
protein amino acid.
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individual basic residues Arg262, Arg263, and Lys265, forming a
second positively charged RRWK cluster (262–265), was suffi-
cient to lead to a large reduction in heparin binding. Mutation
of basic residues Arg19 andArg28, which in the crystal structure
are located next to the two above-mentioned clusters, also led
to a significant reduction in heparin binding, suggesting their
involvement. Mutation of Lys634, which is also spatially closed
to these two clusters, led to a slower rate of binding to heparin,
showing the involvement of this further residue in heparin
interaction. In contrast, neither Lys202 and Lys205 residues nor
the GTP binding site Arg580, which constitutes further accessi-
ble basic sites, was shown to participate in heparin binding.
Our study has led us to conclude that the heparin binding site
on TG2mainly comprises two clusters of basic amino acids, the
RRWK (262–265) and the KQKRK (598–602). These two pos-
itive clusters are distant in the linear sequence; however, they
are brought into spatial proximity on the folded closed protein,
forming the heparin binding site. In this conformation TG2 is
typically bound to guanine or adenine nucleotide and its active
site (Cys277-His335-Asp358 catalytic triad) is obscured as a result
of guanine nucleotide or adenine nucleotide binding (28, 29).
In its active conformation, which was resolved on TG2
bound to irreversible active-site inhibitors, Ca2 binding
involves a large conformational change (41). Although in the
folded conformation the two positive sequences, RRWK
(262–265) and KQKRK (598–602), are spatially close, in the
open active conformation they are spatially distant. Based on
the finding that mutations in these individual clusters very
strongly impaired heparin binding and, thus, that they both
contribute to form a single binding surface, it could be con-
cluded that the open form has a reduced heparin binding
affinity compared with the closed conformation. We tested
this hypothesis and found that the open TG2 form displayed
a strongly reduced ability to bind to heparin compared with
the closed one. This finding supports the view that TG2 fea-
tures two independent heparin binding sites, which are
brought into close proximity in the closed protein, forming a
large interacting basic surface, which is destroyed by the
FIGURE 6. RGD-independent cell adhesion of wt TG2 and TG2 heparin bindingmutants. Swiss 3T3 fibroblasts were allowed to adhere either on FN alone
or FN supplementedwithwt ormutant TG2 (heparin bindingmutantsM1c andM3;mutantswith retained heparin-bindingM2 andM6) in serum-freemedium
for 20 min as described under “Experimental Procedures.” Where indicated cells were preincubated with competitive concentrations of soluble GRGDTP
peptide or control GRADSP peptide (100 g/ml). The degree of cell adhesion was assessed on fixed cells stained with May Grunwald/Giemsa, shown in the
bottompanel, as previously described (19). Each point represents themean number of attached cells (cell attachment) ormean percentage of spread cells (cell
spreading)  S.D. of a representative experiment undertaken in triplicate. Data are expressed as the percentage of control values on FN, which represents
100%. Before normalization,mean attachment values S.D. on FN control were 415 33.Mean percentage values of spread cells on FNwere 81 3; the total
number of quantified cells in the control ranged from 400 to 500 cells in all the type of matrices. Bar, 20 m.
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opening of the structure. This result is also consistent with
the fact that mutations in a single domain are sufficient to
knock down heparin binding. However, such a drastic effect
of a single point mutation on heparin binding has been
observed already, for example, in the chemokine stromal
cell-derived factor-1, where two single mutations were each
able to almost fully inhibit HS recognition (44).
We have also shown that a single heparin-derived pentasac-
charide has the length required to make contacts with the res-
idues of the two basic clusters, RRWK (262–265) and KQKRK
(598–602), of TG2 in the closed conformation. In vivo HS are
present as syndecan or glypican receptors at the cell surface and
perlecans in the basementmembranes (27). Further studies will
be necessary to identify the HS sequences interacting with TG2
and whether the nature of the HS chains composition and their
tissue concentration affects the trafficking/biological activity of
TG2 in different cell compartments.
TG2 ismostly regardedas a latent enzymewhose activity is kept
under tight control to prevent excessive post-translational modi-
fications of protein substrates (12, 45). A demonstration of this is
given by the comparable level of Ca2-dependent TG2 transami-
dation obtained fromconditionedmatriceswith low levels ofTG2
andmatriceswithhigh levels ofTG2, suggesting thatTGactivity is
transient and it is down-regulated by matrix sequestration (19).
There is a clear mechanism of TG2 regulation inside the cells, as
Ca2-dependent transamidation is allosterically inhibited by gua-
nine nucleotide binding and a low Ca2-nucleotide ratio. How-
ever, outside the cell whereTG2 is potentially constantly activated
by high (millimolar) concentrations of Ca2 resulting into a high
Ca2-nucleotide ratio, the mechanism of TG2 regulation it is less
clear. Oxidation of TG2 and formation of critical disulfide bonds
may contribute to its extracellular regulation causing loss of TG2
activity (46), which can be restored by reducing agents (47). It has
alsobeen suggested thatnitrosylationofTG2viaNOmaycontrib-
ute to its transition between active enzyme and “structural matrix
protein” with no required transamidating activity (48). It could be
speculated that short N-sulfoglucosamine-enriched HS
sequences, bridging the RRWK (262–265) and KQKRK (598–
602) sites, could stabilize the closed form and that high calcium
concentrations might indeed partially disrupt the complex and
thus favor the transition toward the open active form. In this way
the interaction with HS may regulate TG2 activity depending on
Ca2/HS microenvironment. An example of regulation of enzy-
matic activity byHSand ionic changeswas previously reported for
elastase and cathepsin G, which are stored in an inactive form,
bound to HS proteoglycans within neutrophil granules, and
released inanactive formbyan increaseof ionic strength (K ions)
(49). Thus, regulation of TG2 activity in the extracellular environ-
ment may be linked to structural changes brought about by HS
proteoglycans structures and Ca2 ions.We previously suggested
thatHSs regulate the cell surface trafficking of TG2 as the absence
of cell surface HS or cells with targeted deletion of sdc-4 do not
effectively externalize TG2 (23, 25). As described for FGF (50), HS
may be effective in trapping and anchoring leaderless TG2 once
exported to thecell surface. In this scenario, the activating concen-
tration of Ca2 in the extracellular space could destabilize the
closed form and the HS interaction, leading to the “release” of
active TG2. Therefore, binding of TG2 to HS via the identified
binding site may be another level of control for extracellular TG2
and have widespread biological consequences/implications, par-
ticularly in the context of cell adhesion, tissue fibrosis, and cancer
progression.
We know that matrix TG2 when in heterocomplex with
fibronectin supports RGD-independent cell adhesion through
ligationof theHSchains of sdc-4. In this studywehave shown that
mutant forms of TG2 lacking either of the two identified heparin
binding clusters supported only weak RGD-independent cell
adhesion compared with wt TG2 or TG2 mutants with retained
heparin binding properties. This finding suggests the requirement
for both heparin binding clusters, RRWK (262–265) and KQKRK
(598–602), for TG2-mediated cell adhesion. It also substantiates
evidence that the cell surface receptor formatrixTG2 is a heparan
sulfate proteoglycan, corroborating the knowledge thatHS chains
regulate the biological function of TG2 at many levels. Although
wedonot knowwhich conformationTG2assumes in heterocom-
plex with fibronectin, we have confirmed that TG2 becomes a
catalytically inactive “structural” protein, which we conclude
retains heparin binding.
Multiple alignments of the human, mouse, and rat TG2 pro-
tein have revealed that the two positive clusters forming the
heparin binding site in the human TG2 sequence are mostly
conserved, with the exception of Lys600, within the KQKRK
(598–602)motif, which is a neutral amino acid (Asn) in rat and
mouse TG2. Among the other contributing residues, Arg19 is
conserved among the different species, but residue Arg28 is a
neutral Gln in rat and mouse TG2. Sequence alignments of
human TG1, TG2, TG3, TG4, TG5, TG6, TG7, and FXIIIa
revealed no obvious homology of the heparin binding sites with
consensus XBBXBX and XBBBXXBX (38) identified in TG2,
with the exception of KQKRK (598–602) in TG3, which is
replaced by another positive cluster (RVRK), and the basic res-
idue Arg-19, which is conserved in TG1. Our preliminary
observations (Biacore analysis) indicate that among the TG
family members we have analyzed, only TG2 and TG1 bind
heparin with high affinity (TG3 and FXIIIa have low heparin
binding affinity). Because the full site is not conserved in TG1,
we conclude that TG2 has a unique heparin binding site within
the family of transglutaminases that could be specifically tar-
geted to control the TG2-HS interaction.
In summary, we have mapped high affinity heparin binding
sites onTG2 that are brought into close proximity on the folded
protein and demonstrated that they influence RGD-indepen-
dent cell adhesion mediated by TG2-fibronectin heterocom-
plex. These data have provided novel insights into the molecu-
lar nature of HS/heparin interaction with TG2 creating new a
hypothesis on how heparan sulfate proteoglycans could regu-
late the extracellular function of TG2.
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